ARTICLE | Company News
Cornerstone Therapeutics, Exela PharmSci Inc. cardiovascular news
August 5, 2013 7:00 AM UTC
Cornerstone filed a suit in the U.S. District Court for the District of Delaware alleging that an sNDA submitted by Exela for an injectable formulation of 0.1 and 0.2 mg/mL nicardipine in 0.9% sodium ...